/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts will be presented at the American Society of Hematology (ASH) Annual.
Key data includes results for intravenous administration of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients DUBLIN